32 results about "URINARY TRYPSIN INHIBITOR" patented technology

The invention relates to a urinary protein enriching method which comprises the steps of directly adsorbing urinary proteins in urine in urinals or urinating buckets with filter cloth bags loaded with modified silica gel, and transporting the urinary protein adsorbed filter cloth bags to working points for subsequent treatment. According to the method, the isoelectric point property of specific urinary proteins is utilized, and urinary proteins such as urinary trypsin inhibitors, human urinary kininogenase, urokinase and the like are effectively absorbed directly by using the modified silica gel, macroporous resin, chitin, ionic resin and the like, so that a urine collecting step is avoided. The method is free of obvious influence on sanitary conditions of toilets, and the cost for urine transportation and a series of environmental problems resulting from urine transportation are greatly reduced.

The invention discloses a method for preparing a human urinary kallidinogenase crude product. The method for preparing the human urinary kallidinogenase crude product comprises the following steps of: after adsorbing urokinase protein in urine for a certain time by using an adsorbing agent, collecting the adsorbing agent in which the urokinase protein is adsorbed and centrally eluting; enabling the eluted urokinase protein solution to pass through a metal chelating affinity chromatography column, wherein a human urinary kallidinogenase inhibiting agent is not adsorbed and the human urinary kallidinogenase is combined onto the metal chelating affinity chromatography column, and the human urinary kallidinogenase inhibiting agent is separated from the human urinary kallidinogenase; and collecting an eluting peak to prepare the human urinary kallidinogenase crude product. Due to the adoption of the technical scheme, the human urinary kallidinogenase is efficiently separated from the humanurinary kallidinogenase inhibition agent in the urine, the subsequent purification treatment for the human urinary kallidinogenase and the human urinary kallidinogenase inhibiting agent is facilitated and the purification yield is increased; and the co-generation of two protein crude products is realized, and thus lower production cost is realized.

Certain monoclonal antibodies are able to detect urinary trypsin inhibitors (UTIs) that are characteristic of disease in humans. In particular, the UTIs include AMBK, Bikunin, Uristatin, Uristatin-1, Uristatin-2, as defined herein, also including the fragments and aggregates thereof.

The invention provides a method for purifying human urinary trypsin inhibitor by utilizing a salt resistant mixed mode adsorbent. The method comprises the following steps: 1) dissolving crude human urinary trypsin inhibitor in water to ensure that the conductance is no less than 30ms / cm after filtration, adjusting the pH value of filtrate to 2-5, then using the salt resistant mixed mode adsorbent to selectively adsorb human urinary trypsin inhibitor; 2) using elution buffer solution of which pH value is 7-10 to elute the salt resistant mixed mode adsorbent, collecting the elution peak product of the human urinary trypsin inhibitor; and 3) performing freeze drying to the elution peak product to obtain high purity human urinary trypsin inhibitor. The invention has the following technical effects: the purification method provided by the invention is characterized in that the method has high purification efficiency and fewer technical steps, is easy to amplify, and the like; and the industrial application of the technology is convenient to realize.

The invention discloses a human urinary trypsin inhibitor (hUTI) of reorganization-dimerization and preparation method and application thereof, wherein the hUTI protein of reorganization-dimerization successively comprises amino acid residue sequence of human UTI, a peptide linker and a human IgGFc variant from N-terminal to C-terminal. The hUTI protein of reorganization-dimerization has the in-vitro biological activity similar with that of the human urinary trypsin inhibitor, higher biological activity in vivo and an extended half-life period in vivo.

The invention belongs to the technical field of medicines, and particularly relates to a method for large-scale production of high-purity ulinastatin (namely human urinary trypsin inhibitor). The method comprises the following steps: mixing chitosan and alginate with urine after preliminary filtration so as to obtain a mixture, and then purifying the mixture in a manner combining ultrafiltration and ethanol fractional precipitation. The method provided by the invention is convenient to operate, high in controllability, simple in purification technology, and suitable for large-scale production; besides, the yield of the ulinastatin is as high as 72%, the molecular weight of protein obtained through purification is 66800D-67200D, and the activity of the ulinastatin for restraining trypsin is higher than 4780IU / mg protein.

A composite medicine in the form of freeze-dried powder injection or liquid injection for treating osteoarthritis and rheumatoid arthritis is prepared from ulinastatin (a human Urinary trypsin inhibitor), sodium hyaluronate and optional mannitol, glycine and dextran.